Identification of Rate-Limiting Steps in the Provision of Thrombolytics for Acute Ischemic Stroke

Abstract

Background:

Tissue plasminogen activator (tPA) is the only pharmacotherapy shown to improve outcomes in acute ischemic stroke. The American Heart Association (AHA) recommends a door-to-needle (DTN) time of <60 minutes in at least 50% of patients presenting with acute ischemic stroke.

Objective:

The purpose of this study was to analyze the possible barriers that may delay tPA administration within the emergency department (ED) of an academic medical center.

Methods:

A retrospective chart review was conducted from February 2011 to October 2013. Patients were included if they were admitted through the ED with a diagnosis of acute ischemic stroke and received tPA.

Results:

Of the 130 patients who met inclusion criteria, 43.1% received tPA in ≤60 minutes. Several factors were identified to be significantly different in those with a DTN time of >60 minutes—time to ED physician consultation, neurologist arrival, blood sample acquisition, and result time (P < .05 for all comparisons). Correlation analysis demonstrated several independent variables associated with DTN time of ≤60 minutes—time from admission to ED physician consultation, receipt of computed tomography (CT) scan, blood sample acquisition, laboratory results, and neurology service arrival (P < .05 for all comparisons).

Conclusion:

The findings from this study highlight the importance of prompt physician evaluation, direct transfer to the CT scanner, and a quick turnaround time on laboratory values. The development of protocols to ensure the rapid receipt of tPA therapy should focus on limiting any potential delay these steps may cause.

Keywords

alteplase ischemic stroke tPA thrombolytics barriers

Get full access to this article

View all access options for this article.

References

Minino

Murphy

. Deaths: final data for 2008. Natl Vital Stat Rep. 2011;59(10):1–126.

Mozaffarian

Benjamin

. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2014;133(4):e38–e360.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. N Eng J Med. 1995;333(24):1581–1587.

Hacke

Kaste

Bluhmki

; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Eng J Med. 2008;359(13):1317–1329.

Hacke

Donnan

Fieschi

; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–774.

Fonarow

Smith

Saver

. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750–758.

Desai

Smith

. Prenotification and other factors involved in rapid tPA administration. Curr Atheroscler Rep. 2013;15(7):337.

Pandya

Ruf

Winstead

. Pharmacy resident participation with a 24-hour multidisciplinary stroke response team. Am J Health Syst Pharm. 2010;67(22):1901, 1905-1907.

Jauch

Saver

Adams

Jr ; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.

10.

Lees

Bluhmki

von Kummer

. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–1703.

11.

Marler

Tilley

. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55(11):1649–1655.

12.

Lansberg

Schrooten

Bluhmki

. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin scale. Stroke. 2009;40(6):2079–2084.

13.

National Institute of Neurological Disorders and Treatment of Acute Stroke. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. December 12-13 1996. Washington, DC; 1997, NIH Publication No. 97-4239. http://www.ninds.nih.gov/news_and_events/proceedings/stroke_proceedings/bock.htm. Accessed August 12, 2013.

14.

Fonarow

Smith

Saver

. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association’s Target: Stroke initiative. Stroke. 2011;42(10):2983–2989.

15.

Nanduri

Tayal

Hegde

. An analysis of discrepancy between point-of-care and central laboratory international normalized ratio testing in ED patients with cerebrovascular disease. Am J Emerg Med. 2012;30(9):2025–2029.